AstraZeneca agrees to make COVID-19 vaccine for Europe
The agreement with AstraZeneca also aims to make the vaccine available to other European countries that wish to take part. This agreement will ensure that hundreds of millions of Europeans have access to Oxford Universitys vaccine following approval, AstraZeneca CEO Pascal Soriot said. The Anglo-Swedish company recently completed similar agreements with Britain, the United States the Coalition for Epidemic Preparedness Innovations, and Gavi, the Vaccine Alliance for 700 million doses. The vaccine was developed by Oxford Universitys Jenner Institute, working with the Oxford Vaccine Group. Testing of the experimental COVID-19 vaccine began in healthy volunteers in Britain in April with over 1,000 people aged 18 to 55.